(Memphis) Today, health officials say ten more people across the country have been diagnosed with fungal meningitis in an outbreak linked to tainted steroid injections.
There was at least one clinic and two West Tennessee hospitals among the 74 found on a health facilities list as having received products from the New England Compounding Center.
NECC is at the center of the moldy medicine being blamed for a deadly outbreak of fungal meningitis.
Dr. Richard Gibbs, a dermatologist with the Center for Dermatology on Poplar Avenue in Memphis said the NECC products that it had were not steroid injectable.
“The products that I purchased from NECC have been exclusively topical medications, which are not related to the type of problems that’s presently in the news or a concern of the health dept and FDA,” Gibbs said.
Dr. Gibbs also said their NECC products have now been boxed up and given to the health department. He said their patients are not in danger, “There is nothing to fear and there’s no health risk coming to my office. None of the things we used or none of the services that I provide are at no risk as far as the present New England Compound pharmacy questions.”
The list also included Saint Francis Hospital-Bartlett on Kate Bond Road.
The hospital didn’t want to talk on camera, but it did release a statement to News Channel Three saying it has not ordered, purchased or used the drug associated with the recent fungal meningitis outbreak from NECC.
It also said as of Monday night the FDA removed the list from its website due to inaccuracies.
Baptist Memorial Hospital-Tipton in Covington was also on the list.
Late today Dr. Paul Depriest, chief medical officer for Baptist said Baptist Memorial Hospital-Tipton does not have any drugs from the New England Compounding Center in any of their facilities.
He said Baptist will continue to cooperate with the FDA and Tennessee Department of Health on this issue.
Saint Francis Hospital – Bartlett has not ordered or used methylprednisolone, the drug associated with the recent fungal meningitis outbreak, from the New England Compounding Center (NECC).
Yesterday the Food and Drug Administration (FDA) posted a list of healthcare facilities that received products shipped from the New England Compounding Center (NECC) on or after May 21, 2012. On its website, the FDA states “The lists were prepared based on information provided by NECC, and the FDA cannot vouch for completeness or accuracy of the lists.” Although the hospital’s name appears on the list as having received methylprednisolone, we have not purchased or received this drug from NECC. As of Monday night, the FDA removed the list from its website due to inaccuracies.
We have purchased other injectable products from the NECC during the time period currently being investigated by the Food and Drug Administration (FDA). All NECC products were removed from our pharmacy inventory on October 4. None of the products previously used by our hospital has been linked to the outbreak of meningitis or other infections. While these drugs have not been linked directly to the outbreak of meningitis or other infections, the FDA has asked all providers to notify patients who may have received them. We are identifying all patients who may be impacted and will notify them via US mail within the week.